A study in humans identified the mir-6760-3p as a potential biomarker for recurrent myocardial infarction risk, demonstrating it was downregulated in whole blood of patients with recurrent MI compared to stable CAD controls after percutaneous coronary intervention, with this differential expression achieving significance after false-discovery rate correction (FDR <0.1) in the replication cohort [Onuoha et al. DOI:10.1111/cts.13307]. The investigation found that the mir-6760-3p was not significantly different in plasma samples, indicating whole blood may be the preferred sample source for miRNA profiling related to thrombotic risk prognosis.